<div id="readability-page-1">MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. ( NUWE ) , a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience. A key feature of the release is a more precise ultrafiltration adjustment capability, reducing the step size to 5 mL/hr from 10 mL/hr. This advancement is particularly important in pediatric care, where small-volume fluid shifts can have a significant clinical impact. “The Aquadex software update reflects our commitment to continuous improvement driven by customer feedback and clinical need,” said Nuwellis’ CEO John Erb. “This release provides clinicians with greater control over fluid management – especially in pediatric patients, which represents our largest and fastest-growing customer category – while also making the system easier to use in demanding care environments.” The update also includes enhancements aimed at improving ease-of-use of the device and therapy visibility, particularly for nursing staff managing day-to-day treatment. Key updates include: <ul type="disc"><li>Refined blood flow algorithm designed to reduce nuisance alarms and improve flow stability;</li><li>Enhanced blood flow resistance graph to provide earlier indication of potential filter clotting ; and</li><li>Expanded hourly data log with additional therapy parameters to support clinical monitoring and documentation. </li></ul> The software update is available to existing customers at no cost and can be deployed through standard update processes with support from Nuwellis’ field and service teams. About Nuwellis ( NUWE ) Nuwellis, Inc. ( NUWE ) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis ( NUWE ) does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: Investor Relations: ir@nuwellis.com Media Contact: CORE PR media@nuwellis.com Image: https://www.globenewswire.com/newsroom/ti?nf=OTY5MzU4NSM3NTQ2MzIzIzIwMTEzMTA= Image: https://ml.globenewswire.com/media/YjU0YzcxZjYtMzMzOS00MzQyLWJkNGUtMzk0M2FlMjEwMDUyLTEwMjI4ODMtMjAyNi0wNC0yMS1lbg==/tiny/Nuwellis-Inc-.png Image: Primary Logo Source: Nuwellis, Inc. ( NUWE )</div>

NUWE

Nuwellis, Inc. 宣布对其 Aquadex SmartFlow® 超滤平台进行软件更新，旨在提升可用性和临床工作流程。此次更新具有更精确的超滤调整能力，特别有利于儿童护理。主要改进包括优化的血流算法、增强的阻力图以及扩展的数据记录。该更新对现有客户免费提供，体现了 Nuwellis 基于客户反馈持续改进的承诺。首席执行官 John Erb 强调了此次更新在儿童患者液体管理中的重要性，这是公司增长最快的客户群体

Nuwellis 宣布 Aquadex 软件的更新